CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population

Multiple Sclerosis

Volumn 12, Issue 4, 2006, Pages 511-514

  Otaegui, D ^a   Saenz A ^a   Camano P ^a   Blazquez L ^a   Goicoechea, M ^a   Ruiz Martinez J ^b   Olaskoaga, J ^a   Emparanza, J A ^a   Lopez de Munain A ^a  

^a HOSPITAL DONOSTIA   (Spain)

^b HOSPITAL DE MENDARO   (Spain)

Author keywords

Association; Basque; CD24; Multiple clerosis; V V

Indexed keywords

ALANINE; CD24 ANTIGEN; VALINE;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; STATISTICAL SIGNIFICANCE;

ADULT; ANTIGENS, CD24; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SPAIN;

EID: 33746537147     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1314sr     Document Type: Article

References (15)

1. Hauser SL, Goodin D. Multiple sclerosis and other demyelinating diseases. In by Braunwald E, Fauci AS, Kasper DL eds. Harrison's principles in internal medicine. McGraw-Hill, 2005: 2461-71.
2. Baranzini SE, Oksenberg JR. Genomics and new targets for multiple sclerosis. Pharmacogenomics 2005; 6: 151-61.
3. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204: 208-31.
4. Zhou D, Rammohan K, Lin S, Robinson N, Li O, Liu X et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100: 15041-46.
5. Goertsches R, Villoslada P, Comabella M, Montalban X, Navarro A, De La Concha EG et al. A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. J Neuroimmunol 2003; 143: 124-28.
6. Haskin Fernald G, Ru-Fang Y, Hauser SL, Oksenberg J, Baranzini SE. Mapping gene activity in complex disorders: integration of expression and genomic scans for multiple sclerosis. J Neuroimmunol 2005; 167: 157-69.
7. Bai XF, Li O, Zhou Q, Zhang H, Joshi P, Zheng X et al. CD24 controls expansion and persistence of auto-reactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J Exp Med 2004; 200: 447-58.
8. Rodríguez-Antiguedad AR. Esclerosis múltiple, análisis clínico retrospectivo y prospectivo de una serie hospitalaria de base poblacional. Thesis/Dissertation, 1999. UPV/EHU.
9. Mallada-Frechin J. Epidemiología descriptiva de la esclerosis múltiple en España. Cuadernos de Esclerosis Múltiple 2003; 16: 59-65.
10. Instituto nacional de estadística (España). Retrieved 2005 from www.ini.es.
11. McDonald W, Compston A, Edan G, Goodkin DE, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel of the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-27.
12. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-51.
13. Calafell F, Bertranpetit J. Principal component analysis of gene frequencies and the origin of Basques. Am J Phys Anthropol 1994; 93: 201-15.
14. de Juan D, Reta A, Castiella A, Pozueta J, Prada A, Cuadrado, E. HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum Genet 2001; 9: 961-64.
15. Otaegui D, Saenz A, Martinez-Zabaleta M, Villoslada. P, Fernández-Manchola I, Alvarez de Arcaya A et al. Mitochondrial haplogroups in Basque multiple sclerosis patients. Mult Scler 2004; 10: 532-35.